PML and triple-negative breast carcinoma: YOD1 regulates the stability of PML/RARα, CDK1, and ITCH, promoting malignant phenotypes in acute promyelocytic leukemia, triple-negative breast cancer, and hepatocellular carcinoma, respectively [18, 24, 36].